Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06468566 Recruiting - Clinical trials for Breast Cancer Female

Identification of Benign and Malignant Breast Nodules Using Ultrasound-modulated Optical Tomography: A Multicenter Study

Start date: February 1, 2024
Phase:
Study type: Observational

Ultrasonic light scattering imaging is a new functional imaging technology that combines traditional B-mode ultrasound imaging and light scattering tomography (DOT). It can improve the accuracy of early diagnosis of breast cancer based on the characteristics of abnormal blood supply and oxygen consumption of lesions. This study aims to evaluate the value of ultrasonic light scattering imaging in the differential diagnosis of benign and malignant breast nodules, and to evaluate the consistency between ultrasonic light scattering imaging and examiners in the differential diagnosis of benign and malignant breast nodules.

NCT ID: NCT06464913 Recruiting - Breast Neoplasms Clinical Trials

Randomized Phase II Trial: Chest Wall RT Omission After Prosthetic Reconstruction

Start date: June 2024
Phase: Phase 2
Study type: Interventional

The goal of this randomized Phase II clinical trial is to test the effects of omitting chest wall radiotherapy (RT) after prosthetic reconstruction in early-stage breast cancer patients. The main questions it aims to answer are: - Can omitting chest wall RT after prosthetic reconstruction reduce the failure rate of breast reconstruction without significantly increasing the local recurrence rate? - Does this approach ensure an improvement in the quality of life for patients without sacrificing therapeutic effectiveness? Participants will: - Be randomly assigned to one of two groups. - One group will receive standard RT to the chest wall and supraclavicular and infraclavicular lymphatic drainage areas. - The other group will have chest wall RT omitted and will only receive RT to the supraclavicular and infraclavicular lymphatic drainage areas. - Participate in follow-up assessments to monitor reconstruction failure rates and local recurrence rates. If there is a comparison group: Researchers will compare the outcomes of the two groups to evaluate the impact of chest wall RT omission on reconstruction failure and local recurrence risks.

NCT ID: NCT06458764 Recruiting - Clinical trials for Breast Cancer Female

Sexual Dysfunction Check-up in Premenopausal Breast Cancer Survivors Taking Endocrine Therapy: A Cross-Sectional Study

SEXCHECK
Start date: May 1, 2023
Phase:
Study type: Observational [Patient Registry]

Primary objectives: - To estimate Sexual Dysfunction (SD) incidence in premenopausal breast cancer patients treated by surgery and taking endocrine therapy. - To detect the presence of SD-related distress in the population, as a determining factor in the maintenance of a good quality of life. Secondary objectives: - To describe SD characteristics determining the most frequently reported symptoms and correlations with type of surgery or therapeutic regimens. - Collect baseline data for subsequent randomized trials involving practical interventions with the aim to reduce SD prevalence in this population.

NCT ID: NCT06458413 Recruiting - Clinical trials for Breast Cancer Recurrent

Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer

Start date: June 5, 2024
Phase: Phase 2
Study type: Interventional

This study aims to investigate the efficacy and safety of utidelone capsule plus Capecitabine in the treatment of advanced breast cancer , and thus provides a new systemic treatment strategy for those patients. This study was a single-arm, phase II study of patients with recurrent or metastatic HER2-negative breast cancer who had previously received chemotherapy regimens containing taxanes and/or anthracyclines were treated with a combination of utidelone capsules and capecitabine. The main objective was to explore the efficacy and safety of the combined regimen.

NCT ID: NCT06456411 Recruiting - Breast Carcinoma Clinical Trials

Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer

Start date: July 12, 2022
Phase:
Study type: Observational

This clinical trial attempts to measure pain severity, location of pain, and feasibility in patients with cancer using functional near-infrared spectroscopy and virtual reality relaxation programs. Functional near-infrared spectroscopy and virtual reality relaxation programs may help relieve pain in patients with cancer who are receiving treatment.

NCT ID: NCT06455904 Recruiting - Breast Cancer Clinical Trials

Effects Of Concentric Cycling Training Protocol During (Neo)Adjuvant Chemotherapy in Breast Cancer Patients: PROTECT-07 Study

PROTECT-07
Start date: May 30, 2024
Phase: N/A
Study type: Interventional

The association of anthracyclines (ANT) and paclitaxel (Tax) is one of the main treatments used in breast cancer. These treatments are known to induce severe side effects such as a decrease in overall exercise capacity (physical condition) in response to muscle and cardiorespiratory alterations. If exercise may be an effective preventive strategy, it seems important to prescribe the most efficient exercise modality. Among them, concentric cycling (i.e., classic cycling) can significantly induce metabolic stimulus, which is needed for maintaining exercise capacity. The PROTECT-07 study aims to demonstrate the superiority of a training program based on concentric cycling during chemotherapy compared to standard treatment. The duration of the training program is 15 weeks with one session per week.

NCT ID: NCT06455657 Recruiting - Breast Cancer Clinical Trials

Breast Cancer Education to Prisoner Women

Start date: May 24, 2024
Phase: N/A
Study type: Interventional

The aim of the study is to determine the effect of breast cancer education given to incarcerated women on breast cancer knowledge and awareness.

NCT ID: NCT06452485 Recruiting - Breast Cancer Clinical Trials

Postoperative Re-irradiaTion With and Without HYPERthermia: Toxicity, Quality of Life and Survival in Patients With Locoregional Recurrent Breast Cancer

RT-HYPE
Start date: January 1, 2024
Phase:
Study type: Observational

In the Netherlands, breast cancer patients with locoregional recurrence (LRR) and high-risk factors are treated with postoperative re-irradiation with or without hyperthermia. Retrospective studies showed that 3-year locoregional control after postoperative re-irradiation with hyperthermia was 68-83%, and severe toxicity in up to 40% of LRR patients. Unfortunately, no prospective (randomized) data are available on clinical outcomes. Consequently, variation exists in hyperthermia-treatment and re-irradiation schedules. Prospective real-world data on oncological outcomes, toxicity and quality of life is highly needed for shared decision-making between patients and professionals. These data will be used in the design of a future randomized trial comparing postoperative re-irradiation and hyperthermia-treatment in high-risk LRR patients.

NCT ID: NCT06447623 Recruiting - Clinical trials for Advanced Breast Cancer

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Start date: February 1, 2024
Phase: Phase 3
Study type: Interventional

This is a randomized, controlled, open-label, phase III study to explore the efficacy and safety of Apatinib in combination with standard first-line endocrine therapy for the HR+/ HER2-SNF4 subtype of advanced breast cancer. The study was used to explore the efficacy of Apatinib in combination with standard endocrine therapy.

NCT ID: NCT06443359 Recruiting - Breast Cancer Clinical Trials

HYPOFRACTIONATED REGIONAL NODAL IRRADIATION IN BREAST CANCER

Start date: November 13, 2018
Phase: N/A
Study type: Interventional

This is a prospective clinical trial designed to evaluate the efficacy and safety of hypofractionated regional nodal irradiation in breast cancer patients. After enrollment, participants will be stratified into 2 Groups based on the extent of axillary surgery. Participants will complete activities and assessments at baseline, and after completion of treatment at 1-2 weeks, 3 months, 6 months, 1 year, 2 year, and 3 years following completion of treatment.